RT Journal Article
SR Electronic
T1 Analysis of Y Chromosome Haplogroups in Parkinson’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.28.22271633
DO 10.1101/2022.02.28.22271633
A1 Grenn, Francis P.
A1 Makarious, Mary B
A1 Bandres-Ciga, Sara
A1 Iwaki, Hirotaka
A1 Singleton, Andrew
A1 Nalls, Mike
A1 Blauwendraat, Cornelis
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/03/02/2022.02.28.22271633.abstract
AB Parkinson’s disease is a complex neurodegenerative disorder that is about 1.5 times more prevalent in males than females. Extensive work has been done to identify the genetic risk factors behind Parkinson’s disease on autosomes and more recently on chromosome X, but work remains to be done on the male specific Y chromosome. In an effort to explore the role of the Y chromosome in Parkinson’s disease we analyzed whole genome sequencing data from the Accelerating Medicines Partnership - Parkinson’s disease initiative (1,466 cases and 1,664 controls), genotype data from NeuroX (3,491 cases and 3,232 controls) and genotype data from UKBiobank (182,517 controls, 1,892 cases, and 3,783 proxy cases) all consisting of male European ancestry samples. We classified sample Y chromosomes by haplogroup using three different tools for comparison (Snappy, Yhaplo, Y-LineageTracker), and meta-analyzed this data to identify haplogroups associated with Parkinson’s disease. This was followed up with a Y chromosome association study to identify specific variants associated with disease. We also analyzed blood based RNASeq data obtained from the Accelerating Medicines Partnership - Parkinson’s disease initiative (1,020 samples) and RNASeq data obtained from the North American Brain Expression Consortium (171 samples) to identify Y chromosome genes differentially expressed in cases, controls, specific haplogroups, and specific tissues. RNASeq analyses suggest Y chromosome gene expression differs between brain and blood tissues but does not differ significantly in cases, controls or specific haplogroups. Overall, we did not find any strong associations between Y chromosome genetics and Parkinson’s disease, suggesting the explanation for increased prevalence in males may lie elsewhere.Competing Interest StatementM.A.N. 's participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research, he also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc.Funding StatementThis study was funded by the National Institutes on Aging.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All AMP-PD (https://amp-pd.org/) and UKBB (https://www.ukbiobank.ac.uk/) data is available via application on their websites and the NeuroX data is available via dbGap at phs000918.v1.p1. NABEC data is available via dbGap at phs001354.v1.p1.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll AMP-PD (https://amp-pd.org/) and UKBB (https://www.ukbiobank.ac.uk/) data is available via application on their websites and the NeuroX data is available via dbGap at phs000918.v1.p1. NABEC data is available via dbGap at phs001354.v1.p1. All code is available on the GitHub page: https://github.com/neurogenetics/chrY_haplogroups_PD https://amp-pd.org/ https://www.ukbiobank.ac.uk/ https://github.com/neurogenetics/chrY_haplogroups_PD